Cargando…

Prime-boost-type PspA3 + 2 mucosal vaccine protects cynomolgus macaques from intratracheal challenge with pneumococci

BACKGROUND: Although vaccination is recommended for protection against invasive pneumococcal disease, the frequency of pneumococcal pneumonia is still high worldwide. In fact, no vaccines are effective for all pneumococcal serotypes. Fusion pneumococcal surface protein A (PspA) has been shown to ind...

Descripción completa

Detalles Bibliográficos
Autores principales: Yokota, Chieko, Fujimoto, Kosuke, Yamakawa, Natsuko, Kono, Masamitsu, Miyaoka, Daichi, Shimohigoshi, Masaki, Uematsu, Miho, Watanabe, Miki, Kamei, Yukari, Sugimoto, Akira, Kawasaki, Natsuko, Yabuno, Takato, Okamura, Tomotaka, Kuroda, Eisuke, Hamaguchi, Shigeto, Sato, Shintaro, Hotomi, Muneki, Akeda, Yukihiro, Ishii, Ken J., Yasutomi, Yasuhiro, Sunami, Kishiko, Uematsu, Satoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10647109/
https://www.ncbi.nlm.nih.gov/pubmed/37964391
http://dx.doi.org/10.1186/s41232-023-00305-2
_version_ 1785147502940389376
author Yokota, Chieko
Fujimoto, Kosuke
Yamakawa, Natsuko
Kono, Masamitsu
Miyaoka, Daichi
Shimohigoshi, Masaki
Uematsu, Miho
Watanabe, Miki
Kamei, Yukari
Sugimoto, Akira
Kawasaki, Natsuko
Yabuno, Takato
Okamura, Tomotaka
Kuroda, Eisuke
Hamaguchi, Shigeto
Sato, Shintaro
Hotomi, Muneki
Akeda, Yukihiro
Ishii, Ken J.
Yasutomi, Yasuhiro
Sunami, Kishiko
Uematsu, Satoshi
author_facet Yokota, Chieko
Fujimoto, Kosuke
Yamakawa, Natsuko
Kono, Masamitsu
Miyaoka, Daichi
Shimohigoshi, Masaki
Uematsu, Miho
Watanabe, Miki
Kamei, Yukari
Sugimoto, Akira
Kawasaki, Natsuko
Yabuno, Takato
Okamura, Tomotaka
Kuroda, Eisuke
Hamaguchi, Shigeto
Sato, Shintaro
Hotomi, Muneki
Akeda, Yukihiro
Ishii, Ken J.
Yasutomi, Yasuhiro
Sunami, Kishiko
Uematsu, Satoshi
author_sort Yokota, Chieko
collection PubMed
description BACKGROUND: Although vaccination is recommended for protection against invasive pneumococcal disease, the frequency of pneumococcal pneumonia is still high worldwide. In fact, no vaccines are effective for all pneumococcal serotypes. Fusion pneumococcal surface protein A (PspA) has been shown to induce a broad range of cross-reactivity with clinical isolates and afford cross-protection against pneumococcal challenge in mice. Furthermore, we developed prime-boost-type mucosal vaccines that induce both antigen-specific IgG in serum and antigen-specific IgA in targeted mucosal organs in previous studies. We investigated whether our prime-boost-type immunization with a fusion PspA was effective against pneumococcal infection in mice and cynomolgus macaques. METHODS: C57BL/6 mice were intramuscularly injected with fusion PspA combined with CpG oligodeoxynucleotides and/or curdlan. Six weeks later, PspA was administered intranasally. Blood and bronchoalveolar lavage fluid were collected and antigen-specific IgG and IgA titers were measured. Some mice were given intranasal Streptococcus pneumoniae and the severity of infection was analyzed. Macaques were intramuscularly injected with fusion PspA combined with CpG oligodeoxynucleotides and/or curdlan at week 0 and week 4. Then, 13 or 41 weeks later, PspA was administered intratracheally. Blood and bronchoalveolar lavage fluid were collected and antigen-specific IgG and IgA titers were measured. Some macaques were intranasally administered S. pneumoniae and analyzed for the severity of pneumonia. RESULTS: Serum samples from mice and macaques injected with antigens in combination with CpG oligodeoxynucleotides and/or curdlan contained antigen-specific IgG. Bronchial samples contained antigen-specific IgA after the fusion PspA boosting. This immunization regimen effectively prevented S. pneumoniae infection. CONCLUSIONS: Prime-boost-type immunization with a fusion PspA prevented S. pneumoniae infection in mice and macaques. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s41232-023-00305-2.
format Online
Article
Text
id pubmed-10647109
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-106471092023-11-15 Prime-boost-type PspA3 + 2 mucosal vaccine protects cynomolgus macaques from intratracheal challenge with pneumococci Yokota, Chieko Fujimoto, Kosuke Yamakawa, Natsuko Kono, Masamitsu Miyaoka, Daichi Shimohigoshi, Masaki Uematsu, Miho Watanabe, Miki Kamei, Yukari Sugimoto, Akira Kawasaki, Natsuko Yabuno, Takato Okamura, Tomotaka Kuroda, Eisuke Hamaguchi, Shigeto Sato, Shintaro Hotomi, Muneki Akeda, Yukihiro Ishii, Ken J. Yasutomi, Yasuhiro Sunami, Kishiko Uematsu, Satoshi Inflamm Regen Research Article BACKGROUND: Although vaccination is recommended for protection against invasive pneumococcal disease, the frequency of pneumococcal pneumonia is still high worldwide. In fact, no vaccines are effective for all pneumococcal serotypes. Fusion pneumococcal surface protein A (PspA) has been shown to induce a broad range of cross-reactivity with clinical isolates and afford cross-protection against pneumococcal challenge in mice. Furthermore, we developed prime-boost-type mucosal vaccines that induce both antigen-specific IgG in serum and antigen-specific IgA in targeted mucosal organs in previous studies. We investigated whether our prime-boost-type immunization with a fusion PspA was effective against pneumococcal infection in mice and cynomolgus macaques. METHODS: C57BL/6 mice were intramuscularly injected with fusion PspA combined with CpG oligodeoxynucleotides and/or curdlan. Six weeks later, PspA was administered intranasally. Blood and bronchoalveolar lavage fluid were collected and antigen-specific IgG and IgA titers were measured. Some mice were given intranasal Streptococcus pneumoniae and the severity of infection was analyzed. Macaques were intramuscularly injected with fusion PspA combined with CpG oligodeoxynucleotides and/or curdlan at week 0 and week 4. Then, 13 or 41 weeks later, PspA was administered intratracheally. Blood and bronchoalveolar lavage fluid were collected and antigen-specific IgG and IgA titers were measured. Some macaques were intranasally administered S. pneumoniae and analyzed for the severity of pneumonia. RESULTS: Serum samples from mice and macaques injected with antigens in combination with CpG oligodeoxynucleotides and/or curdlan contained antigen-specific IgG. Bronchial samples contained antigen-specific IgA after the fusion PspA boosting. This immunization regimen effectively prevented S. pneumoniae infection. CONCLUSIONS: Prime-boost-type immunization with a fusion PspA prevented S. pneumoniae infection in mice and macaques. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s41232-023-00305-2. BioMed Central 2023-11-15 /pmc/articles/PMC10647109/ /pubmed/37964391 http://dx.doi.org/10.1186/s41232-023-00305-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Article
Yokota, Chieko
Fujimoto, Kosuke
Yamakawa, Natsuko
Kono, Masamitsu
Miyaoka, Daichi
Shimohigoshi, Masaki
Uematsu, Miho
Watanabe, Miki
Kamei, Yukari
Sugimoto, Akira
Kawasaki, Natsuko
Yabuno, Takato
Okamura, Tomotaka
Kuroda, Eisuke
Hamaguchi, Shigeto
Sato, Shintaro
Hotomi, Muneki
Akeda, Yukihiro
Ishii, Ken J.
Yasutomi, Yasuhiro
Sunami, Kishiko
Uematsu, Satoshi
Prime-boost-type PspA3 + 2 mucosal vaccine protects cynomolgus macaques from intratracheal challenge with pneumococci
title Prime-boost-type PspA3 + 2 mucosal vaccine protects cynomolgus macaques from intratracheal challenge with pneumococci
title_full Prime-boost-type PspA3 + 2 mucosal vaccine protects cynomolgus macaques from intratracheal challenge with pneumococci
title_fullStr Prime-boost-type PspA3 + 2 mucosal vaccine protects cynomolgus macaques from intratracheal challenge with pneumococci
title_full_unstemmed Prime-boost-type PspA3 + 2 mucosal vaccine protects cynomolgus macaques from intratracheal challenge with pneumococci
title_short Prime-boost-type PspA3 + 2 mucosal vaccine protects cynomolgus macaques from intratracheal challenge with pneumococci
title_sort prime-boost-type pspa3 + 2 mucosal vaccine protects cynomolgus macaques from intratracheal challenge with pneumococci
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10647109/
https://www.ncbi.nlm.nih.gov/pubmed/37964391
http://dx.doi.org/10.1186/s41232-023-00305-2
work_keys_str_mv AT yokotachieko primeboosttypepspa32mucosalvaccineprotectscynomolgusmacaquesfromintratrachealchallengewithpneumococci
AT fujimotokosuke primeboosttypepspa32mucosalvaccineprotectscynomolgusmacaquesfromintratrachealchallengewithpneumococci
AT yamakawanatsuko primeboosttypepspa32mucosalvaccineprotectscynomolgusmacaquesfromintratrachealchallengewithpneumococci
AT konomasamitsu primeboosttypepspa32mucosalvaccineprotectscynomolgusmacaquesfromintratrachealchallengewithpneumococci
AT miyaokadaichi primeboosttypepspa32mucosalvaccineprotectscynomolgusmacaquesfromintratrachealchallengewithpneumococci
AT shimohigoshimasaki primeboosttypepspa32mucosalvaccineprotectscynomolgusmacaquesfromintratrachealchallengewithpneumococci
AT uematsumiho primeboosttypepspa32mucosalvaccineprotectscynomolgusmacaquesfromintratrachealchallengewithpneumococci
AT watanabemiki primeboosttypepspa32mucosalvaccineprotectscynomolgusmacaquesfromintratrachealchallengewithpneumococci
AT kameiyukari primeboosttypepspa32mucosalvaccineprotectscynomolgusmacaquesfromintratrachealchallengewithpneumococci
AT sugimotoakira primeboosttypepspa32mucosalvaccineprotectscynomolgusmacaquesfromintratrachealchallengewithpneumococci
AT kawasakinatsuko primeboosttypepspa32mucosalvaccineprotectscynomolgusmacaquesfromintratrachealchallengewithpneumococci
AT yabunotakato primeboosttypepspa32mucosalvaccineprotectscynomolgusmacaquesfromintratrachealchallengewithpneumococci
AT okamuratomotaka primeboosttypepspa32mucosalvaccineprotectscynomolgusmacaquesfromintratrachealchallengewithpneumococci
AT kurodaeisuke primeboosttypepspa32mucosalvaccineprotectscynomolgusmacaquesfromintratrachealchallengewithpneumococci
AT hamaguchishigeto primeboosttypepspa32mucosalvaccineprotectscynomolgusmacaquesfromintratrachealchallengewithpneumococci
AT satoshintaro primeboosttypepspa32mucosalvaccineprotectscynomolgusmacaquesfromintratrachealchallengewithpneumococci
AT hotomimuneki primeboosttypepspa32mucosalvaccineprotectscynomolgusmacaquesfromintratrachealchallengewithpneumococci
AT akedayukihiro primeboosttypepspa32mucosalvaccineprotectscynomolgusmacaquesfromintratrachealchallengewithpneumococci
AT ishiikenj primeboosttypepspa32mucosalvaccineprotectscynomolgusmacaquesfromintratrachealchallengewithpneumococci
AT yasutomiyasuhiro primeboosttypepspa32mucosalvaccineprotectscynomolgusmacaquesfromintratrachealchallengewithpneumococci
AT sunamikishiko primeboosttypepspa32mucosalvaccineprotectscynomolgusmacaquesfromintratrachealchallengewithpneumococci
AT uematsusatoshi primeboosttypepspa32mucosalvaccineprotectscynomolgusmacaquesfromintratrachealchallengewithpneumococci